Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in Schizophrenia
NCT06572449Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Started Oct 2024; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06572449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572449.